Eye Drop Quality Issues: Can the FDA See This One Through?
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280241233255 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Lyla R White und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Connecticut, Storrs, CT, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Ophthalmic Solutions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
The Food and Drug Administration (FDA) has long suffered from a lack of resources limiting their inspection capacity. They have fallen behind on proactive surveillance inspections of foreign manufacturing sites, relying instead on for-cause inspections after a problem has been discovered. Over-the-counter (OTC) products are especially vulnerable because the FDA considers them lower priority. This issue recently made big news after improperly manufactured OTC eye drops harmed users across the country, in some cases causing blindness. To prevent future harm to Americans, it is imperative that the FDA receives enough resources to keep up with their routine inspections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Connecticut, Storrs, CT, USA.
ORCID-Profile: C Michael White
Zitieren
APA
White, L. R., & White, C. M. (2024). Eye Drop Quality Issues: Can the FDA See This One Through?. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241233255
Vancouver
White LR, White CM. Eye Drop Quality Issues: Can the FDA See This One Through?. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280241233255
BibTeX
@article{White2024,
author = {White, Lyla R and White, C Michael},
title = {Eye Drop Quality Issues: Can the FDA See This One Through?},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280241233255}
}
EUVIMED